Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03162536 · ClinicalTrials.gov registry record · Phase 1
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
A Phase 1 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA).
- Active
- Registry status
- Phase 1
- Development phase
- 190
- Enrollment target
- 10
- Study locations
NCT03162536 is a Phase 1 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA). The registered enrollment target is 190 participants, roughly in line with the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target. The trial reports 10 study locations across 10 states.
The verdict
NCT03162536, a Phase 1 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 190 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.
Conditions Studied
Interventions
- DRUG Nemtabrutinib
Study Locations (10)
Arizona
- Mayo Clinic Hospital ( Site 0140) - Scottsdale
California
- UCLA Hematology & Oncology ( Site 0017) - Los Angeles
Colorado
- Colorado Blood Cancer Institute ( Site 0225) - Denver
Michigan
- University of Michigan ( Site 0018) - Ann Arbor
Minnesota
- Mayo Clinic - Rochester ( Site 0138) - Rochester
North Carolina
- Duke Cancer Center ( Site 0067) - Durham
Ohio
- The Ohio State University Wexner Medical Center ( Site 0056) - Columbus
Tennessee
- Tennessee Oncology, PLLC ( Site 0020) - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2017-06-26 |
| Est. Completion | 2026-09-18 |
| Phase | Phase 1 |
Sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)27 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03162536
The ClinicalTrials.gov registry entry for NCT03162536 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target. The listed sponsor is ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), which has 27 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Nemtabrutinib is the first listed.
NCT03162536 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Arizona, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03162536 about?
NCT03162536 is a clinical study titled "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)". This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.
What is the current status of trial NCT03162536?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 190 participants. The study started on 2017-06-26. Estimated completion is 2026-09-18.
What conditions does trial NCT03162536 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma.
What interventions are being tested in trial NCT03162536?
The interventions under investigation include: Nemtabrutinib (DRUG).
Who is sponsoring clinical trial NCT03162536?
This trial is sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03162536 being conducted?
This trial has 10 study locations across Arizona, California, Colorado, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.